siRNA-EphA2-DOPC

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NamesiRNA-EphA2-DOPC
Drug Alias NamesiEphA2liposomal EphA2 siRNA
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionEphrin type-A receptor 2 modulators
TargetsEphrin type-A receptor 2
Therapy Area/IndicationsSolid tumoursOvarian NeoplasmsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsSolid tumoursOvarian NeoplasmsPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A